Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 1/2021

01-03-2021 | Obesity | Review Article (invited)

Laron syndrome – A historical perspective

Authors: Zvi Laron, Haim Werner

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2021

Login to get access

Abstract

Laron Syndrome (LS) [OMIm#262500], or primary GH insensitivity, was first described in 1966 in consanguineous Jewish families from Yemen. LS is characterized by a typical phenotype that includes dwarfism, obesity and hypogenitalism. The disease is caused by deletions or mutations of the GH-receptor gene, causing high serum GH and low IGF-I serum levels. We studied 75 patients from childhood to adult age. After early hypoglycemia due to the progressive obesity, patients tend to develop glucose intolerance and diabetes. The treatment is by recombinant IGF-I, which improves the height and restores some of the metabolic parameters. An unexpected finding was that patients homozygous for GH-R defects are protected from malignancy lifelong, not so heterozygotes or double heterozygote subjects. We estimate that there are at least 500 patients worldwide, unfortunately only few treated.
Literature
1.
Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab. 2004;89(3):1031–44.PubMedCrossRef
2.
Laron Z, Kowadlo-Silbergeld A, Eshet R, Pertzelan A. Growth hormone resistance. Ann Clin Res. 1980;12(5):269–77.PubMed
3.
Glick SM, Roth J, Yalow RS, Berson SA. Immunoassay of human growth hormone in plasma. Nature. 1963;199:784–7.PubMedCrossRef
4.
Laron Z, Mannheimer S. Measurement of human growth hormone. Description of the method and its clinical applications. Isr J Med Sci. 1966;2(1):115–9.PubMed
5.
Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone-a new inborn error of metabolism? Isr J Med Sci. 1966;2(2):152–5.PubMed
6.
Laron Z, Pertzelan A, Karp M. Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci. 1968;4(4):883–94.PubMed
7.
Keret R, Pertzelan A, Zeharia A, Zadik Z, Laron Z. Growth hormone (hGH) secretion and turnover in three patients with Laron-type dwarfism. Isr J Med Sci. 1988;24(2):75–9.PubMed
8.
Adam A, Josefsberg Z, Pertzelan A, Zadik Z, Chemke JM, Laron Z. Occurrence of four types of growth hormone-related dwarfism in Israeli communities. Eur J Pediatr. 1981;137(1):35–9.PubMedCrossRef
9.
Merimee TJ, Hall J, Rabinowitz D, McKusick VA, Rimoin DL. An unusual variety of endocrine dwarfism: subresponsiveness to growth hormone in a sexually mature dwarf. Lancet. 1968;2(7561):191–3.PubMedCrossRef
10.
Kastrup KW, Andersen H, Hanssen AF. Increased immunoreactive plasma and urinary growth hormone in growth retardation with defective generation of somatomedin a (Laron's syndrome). Acta Paediatr Scand. 1975;64(4):613–8.PubMedCrossRef
11.
Najjar SS, Khachadurian AK, Ilbawi MN, Blizzard RM. Dwarfism with elevated levels of plasma growth hormone. N Engl J Med. 1971;284(15):809–12.PubMedCrossRef
12.
Elders MJ, Garland JT, Daughaday WA, Fisher DA, Whitney JE, Hughes ER. Laron's dwarfism: studies on the nature of the defect. J Pediatr. 1973;83(2):253–63.PubMedCrossRef
13.
Eshet R, Laron Z, Brown M, Arnon R. Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism and high plasma IR-hGH. J Clin Endocrinol Metab. 1973;37(5):819–21.PubMedCrossRef
14.
Eshet R, Peleg S, Josefsberg Z, Fuchs C, Arnon R, Laron Z. Some properties of the plasma hGH activity in patients with Laron-type dwarfism determined by a radio receptor assay using human liver tissue. Horm Res. 1985;22(4):276–83.PubMedCrossRef
15.
Russell RE, Parks JS, McKean MC, Bell GI, Keret R, Kelijman M, et al. Laron-type dwarfism is associated with normal growth hormone and insulin-like growth factor I gene restriction patterns. Isr J Med Sci. 1989;25(6):342–4.PubMed
16.
Laron Z, Pertzelan A, Doron M, Assa S, Keret R. The effect of dihydrosomatostatin in dwarfism with high plasma immunoreactive growth hormone. Horm Metab Res. 1977;9(4):338–9.PubMedCrossRef
17.
Daughaday WH, Laron Z, Pertzelan A, Heins JN. Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Phys. 1969;82:129–40.PubMed
18.
Laron Z, Pertzelan A, Karp M, Kowadlo-Silbergeld A, Daughaday WH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: measurement of sulfation factor, metabolic and linear growth responses. J Clin Endocrinol Metab. 1971;33(2):332–42.PubMedCrossRef
19.
Eshet R, Laron Z, Pertzelan A, Arnon R, Dintzman M. Defect of human growth hormone receptors in the liver of two patients with Laron-type dwarfism. Isr J Med Sci. 1984;20(1):8–11.PubMed
20.
Geffner ME, Golde DW, Lippe BM, Kaplan SA, Bersch N, Li CH. Tissues of the Laron dwarf are sensitive to insulin-like growth factor I but not to growth hormone. J Clin Endocrinol Metab. 1987;64(5):1042–6.PubMedCrossRef
21.
Golde DW, Bersch N, Kaplan SA, Rimoin DL, Li CH. Peripheral unresponsiveness to human growth hormone in Laron dwarfism. N Engl J Med. 1980;303(20):1156–9.PubMedCrossRef
22.
Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z. Wood WI. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A 1989;86(20):8083–8087.
23.
Besson A, Salemi S, Eble A, Joncourt F, Gallati S, Jorge AA, et al. Primary GH insensitivity (Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol. 2004;150(5):635–42.PubMedCrossRef
24.
Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, et al. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med. 1989;321(15):989–95.PubMedCrossRef
25.
Rosenbloom AL. Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. J Pediatr. 1999;135(3):280–9.PubMedCrossRef
26.
Shevah O, Laron Z. Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome. Pediatr Endocrinol Rev. 2006;3(Suppl 3):489–97.PubMed
27.
Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, et al. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab. 1997;82(2):435–7.PubMed
28.
Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. The first homozygous mutation (S226I) in the highly-conserved WSXWS-like motif of the GH receptor causing Laron syndrome: supression of GH secretion by GnRH analogue therapy not restored by dihydrotestosterone administration. Clin Endocrinol. 2004;60(1):36–40.CrossRef
29.
Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, et al. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab. 1997;10(3):265–74.PubMedCrossRef
30.
Rughani A, Zhang D, Vairamani K, Dauber A, Hwa V, Krishnan S. Severe growth failure associated with a novel heterozygous nonsense mutation in the GHR transmembrane domain leading to elevated growth hormone binding protein. Clin Endocrinol. 2020;92(4):331–7.CrossRef
31.
Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab. 1993;76(1):54–9.PubMed
32.
Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab. 1998;83(2):531–7.PubMed
33.
Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, et al. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome. J Clin Endocrinol Metab. 1997;82(11):3705–9.PubMed
34.
Fang P, Riedl S, Amselem S, Pratt KL, Little BM, Haeusler G, et al. Primary growth hormone (GH) insensitivity and insulin-like growth factor deficiency caused by novel compound heterozygous mutations of the GH receptor gene: genetic and functional studies of simple and compound heterozygous states. J Clin Endocrinol Metab. 2007;92(6):2223–31.PubMedCrossRef
35.
Hershkovitz I, Kornreich L, Laron Z. Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron syndrome). Am J Phys Anthropol. 2007;134(2):198–208.PubMedCrossRef
36.
Falk D. The Fossil Chronicles. Berkeley: University of California Press; 2011. p. 152–5.CrossRef
37.
Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJ, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab. 1998;83(7):2554–61.PubMed
38.
Phanse-Gupte SR, Khadilkar VV, Khadilkar AV. Clinical features and endocrine profile of Laron syndrome in Indian children. Indian J Endocrinol Metab. 2014;18(6):863–7.PubMedPubMedCentralCrossRef
39.
40.
Razzaghy-Aza M. Laron syndrome – a review of 8 Iranian patients with Laron syndrome. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966–1992. Basel: Karger; 1993. p. 93–100.
41.
Yordam N, Kandemir N, Erkul I, Kurdoglu S, Hatun S. Review of Turkish patients with growth hormone insensitivity (Laron type). Eur J Endocrinol. 1995;133(5):539–42.PubMedCrossRef
42.
Galli-Tsinopoulou A, Nousia-Arvanitakis S, Tsinopoulos I, Bechlivanides C, Shevah O, Laron Z. Laron syndrome. First report from Greece. Hormones (Athens). 2003;2(2):120–4.CrossRef
43.
Cohen A, Cordone G, Fasce G, Romano C. An additional patient of Laron –type dwarfism in Italy. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966–1992. Basel: Karger; 1993. p. 70–2.
44.
Pierson M, Malaprade D, Fortier G, Belleville F, Lasbennes A, Wuilbereq L. Laron type familial dwarfism; genetic primary somatomedin deficiency. Arch Fr Pediatr. 1978;35(2):151–64.PubMed
45.
Alcaniz JJ, Salto L, Barcelo B. GH secretion in two siblings with Laron's dwarfism: the effects of glucose, arginine, somatostatin, and bromocryptine. J Clin Endocrinol Metab. 1978;47(2):453–6.PubMedCrossRef
46.
Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, et al. Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol Metab. 1997;82(2):444–51.PubMed
47.
Costin G, Roe T, Clemons R, Kogut M. Growth hormone resistance syndrome (Laron-type dwarfism). In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966–1992. Basel: Karger; 1993. p. 73–80.
48.
Rosenbloom AL, Guevara Aguirre J, Rosenfeld RG, Fielder PJ. The little women of Loja--growth hormone-receptor deficiency in an inbred population of southern Ecuador. N Engl J Med. 1990;323(20):1367–74.PubMedCrossRef
49.
Saldanha PH, Toledo SP. Familial dwarfism with high IR-GH: report of two affected sibs with genetic and epidemiologic considerations. Hum Genet. 1981;59(4):367–72.PubMedCrossRef
50.
de Lima Jorge AA, de Menezes Filho HC, Soares Lins TS, Guedes DR, Damiani D, Setian N, et al. Efeito fundador la mutacao E180splice no Gene do Receptor de Hormonio de Crescimento Identificada em Pacientes Brasileiros Com Insensibilidade ao GH. Arq Bras Endocinol Metab. 2005;49(3):384–9.CrossRef
51.
Arriazu MC, Gonzalez A. The first reported case of Laron –type dwarfism in Argentina. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966–1992. Basel: Karger; 1993. p. 101–3.
52.
Goncalves FT, Fridman C, Pinto EM, Guevara-Aguirre J, Shevah O, Rosembloom AL, et al. The E180splice mutation in the GHR gene causing Laron syndrome: witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World? Am J Med Genet A. 2014;164A(5):1204–8.PubMedCrossRef
53.
Laron Z. Diagnosis of Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Berlin Heidelberg: Springer Verlag; 2011. p. 27–8.CrossRef
54.
Laron Z, Pertzelan A, Karp M, Keret R, Eshet R. Silbergeld. A 1993 Laron syndrome – a unique model of IGF-I deficiency. In: Laron Z, Parks JS, editors. Lessons from Laron syndrome (LS) 1966–1992. Basel: Karger; 1993. p. 3–23.
55.
Laron Z, Kauli R. Linear growth pattern of untreated Laron syndrome patients. In: Laron Z, Kopchick JJ, editors. Laron Syndrome from Man to Mouse. Berlin: Springer Verlag; 2011. p. 63–89.CrossRef
56.
Konen O, Silbergeld A, Lilos P, Kornreich L, Laron Z. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome. J Pediatr Endocrinol Metab. 2009;22(3):235–9.PubMedCrossRef
57.
Scharf A, Laron Z. Skull changes in pituitary dwarfism and the syndrome of familial dwarfism with high plasma immunoreactive growth hormone--a Roentgenologic study. Horm Metab Res. 1972;4(2):93–7.PubMedCrossRef
58.
Konfino R, Pertzelan A, Laron Z. Cephalometric measurements of familial dwarfism and high plasma immunoreactive growth hormone. Am J Orthod. 1975;68(2):196–201.PubMedCrossRef
59.
Lurie R, Ben-Amitai D, Laron Z. Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair. Dermatology. 2004;208(4):314–8.PubMedCrossRef
60.
Bourla DH, Laron Z, Snir M, Lilos P, Weinberger D, Axer-Siegel R. Insulin like growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome. Ophthalmology. 2006;113(7):1197.e1191–5.CrossRef
61.
Laron Z. The teeth in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron Syndrome from Man to Mouse. Berlin: Springer Verlag; 2011. p. 213–7.CrossRef
62.
Attias J, Zarchi O, Nageris BI, Laron Z. Cochlear hearing loss in patients with Laron syndrome. Eur Arch Otorhinolaryngol. 2012;269(2):461–6.PubMedCrossRef
63.
Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm Res. 1993;40(1–3):16–22.PubMedCrossRef
64.
Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol. 2006;65(1):114–7.CrossRef
65.
Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Hormon IGF Res. 2008;18(5):434–8.CrossRef
66.
Kanety H, Hemi R, Ginsberg S, Pariente C, Yissachar E, Barhod E, et al. Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur J Endocrinol. 2009;161(6):837–44.PubMedCrossRef
67.
Laron Z, Avitzur Y, Klinger B. Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Metabolism. 1995;44(10 Suppl 4):113–8.PubMedCrossRef
68.
Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol. 2004;151(1):103–6.PubMedCrossRef
69.
Dagan Y, Abadi J, Lifschitz A, Laron Z. Severe obstructive sleep apnoea syndrome in an adult patient with Laron syndrome. Growth Hormon IGF Res. 2001;11(4):247–9.CrossRef
70.
Laron Z. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). J Pediatr Endocrinol Metab. 1999;12(Suppl 1):231–49.PubMed
71.
Laron Z, Sarel R. Penis and testicular size in patients with growth hormone insufficiency. Acta Endocrinol. 1970;63(4):625–33.CrossRef
72.
73.
Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol. 2000;85(2):209–13.PubMedCrossRef
74.
Brat O, Ziv I, Klinger B, Avraham M, Laron Z. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I-treated patients with growth hormone deficiency or Laron syndrome. Horm Res. 1997;47(2):45–8.PubMedCrossRef
75.
Ben-Dov I, Gaides M, Scheinowitz M, Wagner R, Laron Z. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome). Clin Endocrinol. 2003;59(6):763–7.CrossRef
76.
Kornreich L, Horev G, Schwarz M, Karmazyn B, Laron Z. Craniofacial and brain abnormalities in Laron syndrome (primary growth hormone insensitivity). Eur J Endocrinol. 2002;146(4):499–503.PubMedCrossRef
77.
Kornreich L, Konen O, Schwarz M, Siegel Y, Horev G, Hershkovitz I, et al. Abnormalities of the axial and proximal appendicular skeleton in adults with Laron syndrome (growth hormone insensitivity). Skelet Radiol. 2008;37(2):153–60.CrossRef
78.
Benbassat CA, Eshed V, Kamjin M, Laron Z. Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities. J Clin Endocrinol Metab. 2003;88(10):4586–9.PubMedCrossRef
79.
Laron Z. Clinical evidence of growth hormone resistance in patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron Syndrome from Man to Mouse. Berlin: Springer Verlag; 2011. p. 21–5.CrossRef
80.
Laron Z, Klinger B, Erster B, Anin S. Effect of acute administration of insulin-like growth factor I n patients with Laron-type dwarfism. Lancet. 1988;2(8621):1170–2.PubMedCrossRef
81.
Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet. 1992;339(8804):1258–61.PubMedCrossRef
82.
Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 1995;8(3):149–58.PubMedCrossRef
83.
Laron Z. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev. 2008;5(3):766–71.PubMed
84.
Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Hormon IGF Res. 2006;16(1):61–4.CrossRef
85.
Laron Z, Klinger B. IGF-I treatment of adult patients with Laron syndrome: preliminary results. Clin Endocrinol. 1994;41(5):631–8.CrossRef
86.
Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism. 1996;45(10):1263–6.PubMedCrossRef
87.
Barazani C, Werner H, Laron Z. Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - a pilot study. Growth Hormon IGF Res. 2020;52:101312.CrossRef
88.
Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab. 2003;16(4):509–20.PubMedCrossRef
89.
Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol. 1998;138(2):176–80.PubMedCrossRef
90.
Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol. 1998;48(1):81–7.CrossRef
91.
Laron Z. Adverse effects encountered during IGF-I treatment of patients with Laron syndrome. In: Laron Z, Kopchick JJ, editors. Laron syndrome from man to mouse. Berlin: Springer Verlag; 2011. p. 419–26.CrossRef
92.
Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Hormon IGF Res. 2007;17(1):54–7.CrossRef
93.
Steuerman R, Shevah O, Laron Z. Congenital IGF-I deficiency tends to confer protection against postnatal development of malignancies. Eur J Endocrinol. 2011;164:485–9.PubMedCrossRef
94.
Renehan AG, Zwahlen MCM, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.PubMedCrossRef
95.
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:0ra13.CrossRef
96.
Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology. 2005;146:5188–96.PubMedCrossRef
97.
Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, LeRoith D, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor-I levels. Cancer Res. 2008;68:3680–8.PubMedCrossRef
98.
Lapkina-Gendler L, Rotem I, Pasmanik-Chor M, Gurwitz D, Sarfstein R, Laron Z, et al. Identification of signaling pathways associated with cancer protection in Laron syndrome. Endocr Relat Cancer. 2016;23:399–410.PubMedCrossRef
99.
Werner H, Lapkina-Gendler L, Laron Z. Fifty years on: new lessons from Laron syndrome. Isr Med Assoc J. 2017;19:6–7.PubMed
100.
Werner H, Lapkina-Gendler L, Achlaug L, Nagaraj K, Somri L, Yaron-Saminsky D, et al. Genome-wide profiling of Laron syndrome patients identifies novel cancer protection pathways. Cells (Basel). 2019;8:596.
101.
Nagaraj K, Lapkina-Gendler L, Sarfstein R, Gurwitz D, Pasmanik-Chor M, Laron Z, et al. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action. Proc Natl Acad Sci U S A. 2018;115:1045–50.PubMedPubMedCentralCrossRef
Metadata
Title
Laron syndrome – A historical perspective
Authors
Zvi Laron
Haim Werner
Publication date
01-03-2021
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 1/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09595-0

Other articles of this Issue 1/2021

Reviews in Endocrine and Metabolic Disorders 1/2021 Go to the issue

ReviewPaper

The continuum between GH deficiency and GH insensitivity in children

ReviewPaper

Genetic causes of growth hormone insensitivity beyond GHR

ReviewPaper

Mouse models of growth hormone insensitivity

ReviewPaper

Current concepts of the diagnosis of adult growth hormone deficiency

ReviewPaper

Growth hormone and aging

ReviewPaper

Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits